Eli Lilly & Co. (LLY) Tops Q3 EPS by 113c; raises guidance

Eli Lilly & Co. (NYSE: LLY) reported Q3 EPS of $7.02, $1.13 better than the analyst estimate of $5.89. Revenue for the quarter came in at $17.6 billion versus the consensus estimate of $16.07 billion.

GUIDANCE:

Eli Lilly & Co. sees FY2025 EPS of $23.00-$23.70, versus the consensus of $22.50. Eli Lilly & Co. sees FY2025 revenue of $63-63.5 billion, versus the consensus of $61.63 billion.

For earnings history and earnings-related data on Eli Lilly & Co. (LLY) click here.

You May Also Be Interested In

• Eli Lilly (LLY) PT Raised to $1,284 at Guggenheim
• Teva shares Phase 3 data on once-monthly schizophrenia injection
• SmartKem (SMTK) files for 15.13M share offering by selling stockholders